Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetics, PK, in healthy male volunteers following the administration of mosliciguat, a potential first-in-class, inhaled soluble Guanylate Cyclase activator with targeted delivery to the lungs and once-daily administration, designed to provide a treatment option for patients with pulmonary hypertension. The peer-reviewed manuscript titled, “Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat: Results from Randomized Phase I Studies in Healthy Men,” was published in the scientific journal Clinical Pharmacokinetics. These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Strategic Growth and Orphan Drug Success Drive Buy Rating for Roivant Sciences
- Roivant Sciences Reports Progress and Financial Results
- Roivant Sciences Earnings Call: Balancing Growth and Challenges
- Roivant Sciences reports Q4 EPS (29c), consensus (16c)
- Roivant Sciences: Strategic Leadership and Promising Developments Drive Buy Rating